ID

12650

Beskrivning

Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT; ODM derived from: https://clinicaltrials.gov/show/NCT00840853

Länk

https://clinicaltrials.gov/show/NCT00840853

Nyckelord

  1. 2015-12-07 2015-12-07 -
Uppladdad den

7 december 2015

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0

Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Acute Lymphoblastic Leukemia (ALL) NCT00840853

Eligibility Acute Lymphoblastic Leukemia (ALL) NCT00840853

Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
any patient regardless of sex or age with cd19+ b-all undergoing allogeneic hsct (group a)
Beskrivning

any patient regardless of sex or age with cd19+ b-all undergoing allogeneic hsct (group a)

Datatyp

boolean

Alias
UMLS CUI [1]
C2698589
UMLS CUI [2]
C0006413
UMLS CUI [3]
C1705576
or any patient regardless of sex or age with cd19+ b-cll or nhl undergoing allogeneic hsct (group b).
Beskrivning

or any patient regardless of sex or age with cd19+ b-cll or nhl undergoing allogeneic hsct (group b)

Datatyp

boolean

Alias
UMLS CUI [1]
C2698589
UMLS CUI [2]
C0023434
UMLS CUI [3]
C0024305
UMLS CUI [4]
C1705576
with minimal residual disease (mrd) or relapse post-hsct (for the phase i dose escalation)
Beskrivning

with minimal residual disease (mrd) or relapse post-hsct (for the phase i dose escalation)

Datatyp

boolean

Alias
UMLS CUI [1]
C0543478
UMLS CUI [2]
C0277556
with no evidence of all or cll/nhl post-hsct (to be included in the expansion cohort
Beskrivning

with no evidence of all or cll/nhl post-hsct (to be included in the expansion cohort

Datatyp

boolean

Alias
UMLS CUI [1]
C0153876
UMLS CUI [2]
C1705576
patients with life expectancy greater than or equal to 6 weeks
Beskrivning

life expectancy

Datatyp

boolean

Alias
UMLS CUI [1]
C0023671
patients with a karnofsky/lansky score greater than or equal to 50
Beskrivning

karnofsky/lansky score

Datatyp

boolean

Alias
UMLS CUI [1]
C0206065
donor hiv negative
Beskrivning

donor hiv negative

Datatyp

boolean

Alias
UMLS CUI [1]
C0481430
5. patient or parent/guardian capable of providing informed consent
Beskrivning

informed consent

Datatyp

boolean

Alias
UMLS CUI [1]
C0021430
patients with bilirubin 2x normal or less, ast 3x normal or less, creatinine less than or equal to 2x normal for age and hgb greater than 8.0
Beskrivning

patients with bilirubin 2x normal or less, ast 3x normal or less, creatinine less than or equal to 2x normal for age and hgb greater than 8.0

Datatyp

boolean

Alias
UMLS CUI [1]
C1278039
UMLS CUI [2]
C0428321
UMLS CUI [3]
C0201976
UMLS CUI [4]
C0019046
pulse oximetry of greater than 90 percent on room air
Beskrivning

pulse oximetry

Datatyp

boolean

Alias
UMLS CUI [1]
C0034108
sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the ctl infusion. the male partner should use a condom.
Beskrivning

sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the ctl infusion. the male partner should use a condom.

Datatyp

boolean

Alias
UMLS CUI [1]
C0700589
available allogeneic cd19car transduced tri-virus-specific cytotoxic t lymphocytes with greater than or equal to 15 percent expression of cd19car determined by flow-cytometry and greater than 10 percent killing of one or more viral antigen pulsed targets in a cytotoxicity assay at an effector:target ratio of 20:1.*
Beskrivning

available allogeneic cd19car transduced tri-virus-specific cytotoxic t lymphocytes with greater than or equal to 15 percent expression of cd19car determined by flow-cytometry and greater than 10 percent killing of one or more viral antigen pulsed targets in a cytotoxicity assay at an effector:target ratio of 20:1.*

Datatyp

boolean

Alias
UMLS CUI [1]
C2981182
UMLS CUI [2]
C0201622
patients should have been off other investigational antiviral or antitumor therapy for one month prior to entry in this study.
Beskrivning

study subject participation status

Datatyp

boolean

Alias
UMLS CUI [1]
C2348568
note: cell dose is based on total cell numbers and not individual antivirus or antileukemic cell numbers.
Beskrivning

note: cell dose is based on total cell numbers and not individual antivirus or antileukemic cell numbers

Datatyp

boolean

Alias
UMLS CUI [1]
C0005771
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
severe intercurrent infection
Beskrivning

infection

Datatyp

boolean

Alias
UMLS CUI [1]
C0009450
evidence of graft versus host disease >grade ii
Beskrivning

graft versus host disease

Datatyp

boolean

Alias
UMLS CUI [1]
C0018133
pregnant or lactating
Beskrivning

pregnant or lactating

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0006147
history of hypersensitivity reactions to murine protein-containing products.
Beskrivning

history of hypersensitivity reactions to murine protein-containing products.

Datatyp

boolean

Alias
UMLS CUI [1]
C0020517
UMLS CUI [2]
C1699668
currently taking corticosteroids for therapy of gvhd.
Beskrivning

corticosteroids gvhd

Datatyp

boolean

Alias
UMLS CUI [1]
C0149783

Similar models

Eligibility Acute Lymphoblastic Leukemia (ALL) NCT00840853

Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
any patient regardless of sex or age with cd19+ b-all undergoing allogeneic hsct (group a)
Item
any patient regardless of sex or age with cd19+ b-all undergoing allogeneic hsct (group a)
boolean
C2698589 (UMLS CUI [1])
C0006413 (UMLS CUI [2])
C1705576 (UMLS CUI [3])
or any patient regardless of sex or age with cd19+ b-cll or nhl undergoing allogeneic hsct (group b)
Item
or any patient regardless of sex or age with cd19+ b-cll or nhl undergoing allogeneic hsct (group b).
boolean
C2698589 (UMLS CUI [1])
C0023434 (UMLS CUI [2])
C0024305 (UMLS CUI [3])
C1705576 (UMLS CUI [4])
with minimal residual disease (mrd) or relapse post-hsct (for the phase i dose escalation)
Item
with minimal residual disease (mrd) or relapse post-hsct (for the phase i dose escalation)
boolean
C0543478 (UMLS CUI [1])
C0277556 (UMLS CUI [2])
with no evidence of all or cll/nhl post-hsct (to be included in the expansion cohort
Item
with no evidence of all or cll/nhl post-hsct (to be included in the expansion cohort
boolean
C0153876 (UMLS CUI [1])
C1705576 (UMLS CUI [2])
life expectancy
Item
patients with life expectancy greater than or equal to 6 weeks
boolean
C0023671 (UMLS CUI [1])
karnofsky/lansky score
Item
patients with a karnofsky/lansky score greater than or equal to 50
boolean
C0206065 (UMLS CUI [1])
donor hiv negative
Item
donor hiv negative
boolean
C0481430 (UMLS CUI [1])
informed consent
Item
5. patient or parent/guardian capable of providing informed consent
boolean
C0021430 (UMLS CUI [1])
patients with bilirubin 2x normal or less, ast 3x normal or less, creatinine less than or equal to 2x normal for age and hgb greater than 8.0
Item
patients with bilirubin 2x normal or less, ast 3x normal or less, creatinine less than or equal to 2x normal for age and hgb greater than 8.0
boolean
C1278039 (UMLS CUI [1])
C0428321 (UMLS CUI [2])
C0201976 (UMLS CUI [3])
C0019046 (UMLS CUI [4])
pulse oximetry
Item
pulse oximetry of greater than 90 percent on room air
boolean
C0034108 (UMLS CUI [1])
sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the ctl infusion. the male partner should use a condom.
Item
sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the ctl infusion. the male partner should use a condom.
boolean
C0700589 (UMLS CUI [1])
available allogeneic cd19car transduced tri-virus-specific cytotoxic t lymphocytes with greater than or equal to 15 percent expression of cd19car determined by flow-cytometry and greater than 10 percent killing of one or more viral antigen pulsed targets in a cytotoxicity assay at an effector:target ratio of 20:1.*
Item
available allogeneic cd19car transduced tri-virus-specific cytotoxic t lymphocytes with greater than or equal to 15 percent expression of cd19car determined by flow-cytometry and greater than 10 percent killing of one or more viral antigen pulsed targets in a cytotoxicity assay at an effector:target ratio of 20:1.*
boolean
C2981182 (UMLS CUI [1])
C0201622 (UMLS CUI [2])
study subject participation status
Item
patients should have been off other investigational antiviral or antitumor therapy for one month prior to entry in this study.
boolean
C2348568 (UMLS CUI [1])
note: cell dose is based on total cell numbers and not individual antivirus or antileukemic cell numbers
Item
note: cell dose is based on total cell numbers and not individual antivirus or antileukemic cell numbers.
boolean
C0005771 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
infection
Item
severe intercurrent infection
boolean
C0009450 (UMLS CUI [1])
graft versus host disease
Item
evidence of graft versus host disease >grade ii
boolean
C0018133 (UMLS CUI [1])
pregnant or lactating
Item
pregnant or lactating
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
history of hypersensitivity reactions to murine protein-containing products.
Item
history of hypersensitivity reactions to murine protein-containing products.
boolean
C0020517 (UMLS CUI [1])
C1699668 (UMLS CUI [2])
corticosteroids gvhd
Item
currently taking corticosteroids for therapy of gvhd.
boolean
C0149783 (UMLS CUI [1])

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial